Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Search
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
Celebrating Innovation | Partnering
BI’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of entrepreneurs in advancing new ideas & science.
What to Expect from Your Vaccine | Boehringer Ingelheim US
Read more on how horse owners are encouraged to schedule a wellness exam with their veterinarians, including annual equine vaccinations.
3FLEX® 250-Dose Option & Vaccine Mixing | Boehringer Ingelheim US
Click here to find out more about Boehringer Ingelheim's 3FLEX® 250-Dose option & new vaccine mixing procedures, preventing major swine respiratory disease.
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
Innovation in Immunology | Human Health | Boehringer Ingelheim US
BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.
Sustainable Development for Generations | Boehringer Ingelheim US
At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.
Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
Innovation in Oncology and Cancer Immunology
Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
Heart Diseases
Heart Diseases
Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
Submit Your Partnering Opportunity
Submit Your Partnering Opportunity
Overcoming stigma and advancing lung cancer advocacy
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Press Material
Find the latest press releases from Boehringer Ingelheim on animal health or access our media pool to view BI corporate news.
Partnering Culture
BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
Boehringer Ingelheim wins 2023 Prix Galien USA
Boehringer Ingelheim wins 2023 Prix Galien USA 2023 Prix Galien USA Best Orphan/Rare Disease Solution Award
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
Expert insights: top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Cafeteria Crews Cook for Community | Boehringer Ingelheim US
Read more on how BI cafeteria crews are supporting their communities by cooking over 500 meals a day for first responders & others during the pandemic.
Partnering Days
Partnering Days
Boehringer inhalers now available at $35 a month for eligible patients
Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients